a<p>Intermittent preventive treatment of malaria in pregnancy with sulphadoxine-pyrimethamine.</p>b<p>Tringular distribution was chosen to be consistent with previous similar studies <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0013407#pone.0013407-Hutton1" target="_blank">[53]</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0013407#pone.0013407-Conteh1" target="_blank">[58]</a>.</p>c<p>in US$ 2007.</p>d<p>Rate per person-year at risk in the placebo group.</p>e<p>It indicates the proportion of pregnant women with symptoms of malaria who seek formal health care. The values of the uniform distribution are adapted from Hutton et al <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0013407#pone.0013407-Hutton1" target="_blank">[53]</a></p>f<p>It is assumed that severe cases = hospitalized cases</p>g<p>The left limit of the confidence interval is negative due to bootstrapping.</p>h<p>Drug costs for inpatients refers to intravenous quinine.</p>i<p>Drug costs for outpatients refers to artesunate plus SP.</p>l<p>Seven newborns died during the first 28 days of life for each 495 pregnant women receiving SP and 18 newborns died for 493 pregnant women receiving placebo. Reduction of deaths per 1000 mothers receiving SP is equal to [number of deaths averted/number of mothers in SP group]*1000.</p
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.